Acute kidney injury and COVID-19.

Published in: The Egyptian journal of internal medicine (2021)

COVID-19 may associate with AKI due to direct effect of SARS-CoV-2 through ACE2 and DPP4 receptors or indirectly through the development of cytokine storm. Both ACE2 and DPP4 are interacted mutually in the pathogenesis of AKI. Thus, DPP4 inhibitors or ACE2 activators could reverse early AKI in COVID-19. Therefore, emerging of clinical trials is warranted to confirm the role of ACE2 and DPP4 modulators in COVID-19-induced AKI.

Keyphrases

sars cov
acute kidney injury
coronavirus disease
cardiac surgery
angiotensin converting enzyme
respiratory syndrome coronavirus
angiotensin ii
clinical trial
small molecule
study protocol
phase ii